The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?
Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …
Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review
Background: Cancer immunotherapy with checkpoint inhibitors (CPIs) is associated with
frequent immune-related adverse events (irAEs) and is often not recommended for patients …
frequent immune-related adverse events (irAEs) and is often not recommended for patients …
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Abstract Background Checkpoint inhibitors (CPIs) have revolutionized the treatment of
cancer, but their use remains limited by off-target inflammatory and immune-related adverse …
cancer, but their use remains limited by off-target inflammatory and immune-related adverse …
Immune checkpoint inhibitors in challenging populations
Immune checkpoint inhibitors, including those targeting the programmed cell death
1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are …
1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are …
[HTML][HTML] Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
MA Perazella, AC Shirali - Kidney International, 2020 - Elsevier
Immune checkpoint inhibitors have dramatically improved cancer therapy for many patients.
These humanized monoclonal antibodies against various immune checkpoints (receptors …
These humanized monoclonal antibodies against various immune checkpoints (receptors …
Cancer in kidney transplant recipients
Cancer is the second most common cause of mortality and morbidity in kidney transplant
recipients after cardiovascular disease. Kidney transplant recipients have at least a twofold …
recipients after cardiovascular disease. Kidney transplant recipients have at least a twofold …
The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature
V Kumar, AB Shinagare, HG Rennke, S Ghai… - The …, 2020 - academic.oup.com
Limited data exist on safety and efficacy of immune checkpoint inhibitors (ICIs) among organ
transplant recipients. The objective of this study was to report a case series of two patients …
transplant recipients. The objective of this study was to report a case series of two patients …
[HTML][HTML] Checkpoint Inhibitors: the diagnosis and treatment of side effects
L Heinzerling, EN de Toni, G Schett… - Deutsches Ärzteblatt …, 2019 - ncbi.nlm.nih.gov
Background Treatment with checkpoint inhibitors such as anti-programmed death-1 (anti-PD-
1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) …
1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) …
Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review
Background The use of immunotherapies in the treatment of metastatic cancers has
significantly advanced oncology. However, due to safety concerns, solid organ transplant …
significantly advanced oncology. However, due to safety concerns, solid organ transplant …
[HTML][HTML] Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience
TT DeLeon, MA Salomao, BA Aqel… - Journal of …, 2018 - ncbi.nlm.nih.gov
Background Patients with solid organ transplants (SOTs) have been excluded from
programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical …
programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical …